StockData
Pacira BioSciences, Inc. logo

Pacira BioSciences, Inc. (PCRX) stock

PCRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3028% above fair value
$36.48+0.00 (0.00%)

Close on Nov 17, 2026Market cap $1.45BP/E 104.2Yield –

Pacira BioSciences pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Pacira BioSciences's pe ratio was 104.2× on Nov 11, 2026, against 51.2× a year earlier. Over the last 5 years it ranged from 10.9× to 258.2×, with a median of 66.5×.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 2026104.2×+47.9
2025Dec 31, 202556.3×+44.2
2024Oct 31, 202412.0×−212.3
2023Dec 29, 2023224.3×+132.4
2022Dec 30, 202291.9×+47.7
2021Dec 31, 202144.2×+23.2
2020Dec 31, 202021.1×−217.1
2019Oct 31, 2019238.2×–

More Pacira BioSciences figures

See a number that looks wrong?